Report topline data from the 4WARD Phase 3 chronic neutropenia trial
Deadline not yet reached (612 days left)
- Announced
- 8 Sep 2026
- Due
- 30 Jun 2028
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“report topline data in the first half of 2028”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 30 Jun 2028.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 8 Sep 2026
Deadline 30 Jun 2028 (“in the first half of 2028”)
-
Version 2 · stated 8 Oct 2026
Deadline 30 Jun 2028 (“in the first half of 2028”) · wording expected
“We expect to reach several key milestones in the near term, including completing enrollment in our Phase 3 4WARD trial this year and reporting topline results in the first half of 2028.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you X4 Pharmaceuticals, Inc? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-XFOR-000471 · Corrections policy